Heparin Crisis Spurs Changes In FDA Emergency Response Policies
Internal and external evaluations of FDA’s handling of the heparin contamination crisis two years ago have led to changes in the agency’s emergency response strategy and a new policy on emergency collaborations with outside experts.
You may also be interested in...
A Government Accountability Office report criticizing FDA's retention of outside experts on heparin contamination spurs disclosure and conflict-of-interest screening policies for emergency situations.
The Republican takeover in the House shuffles the leadership in committees crucial to the dietary supplement and OTC drug industries while likely setting the stage for cuts to FDA funding.
Allegations in Amphastar Pharmaceuticals’ lawsuit over FDA detention of heparin raw ingredient shipments suggest approval of its enoxaparin ANDA, the generic of Sanofi-Aventis’ low-molecular weight heparin Lovenox, is far from imminent.